HC Wainwright Reaffirms “Neutral” Rating for Agenus (NASDAQ:AGEN)

HC Wainwright reiterated their neutral rating on shares of Agenus (NASDAQ:AGEN) in a research note released on Wednesday morning,Benzinga reports.

Agenus Price Performance

Agenus stock opened at $1.87 on Wednesday. The firm has a 50 day simple moving average of $3.23 and a 200-day simple moving average of $3.84. Agenus has a 1-year low of $1.86 and a 1-year high of $19.69. The stock has a market cap of $43.87 million, a price-to-earnings ratio of -0.17 and a beta of 1.23.

Agenus (NASDAQ:AGEN) last posted its quarterly earnings results on Tuesday, March 11th. The biotechnology company reported ($2.04) earnings per share for the quarter, beating the consensus estimate of ($2.36) by $0.32. The firm had revenue of $26.84 million during the quarter, compared to analysts’ expectations of $30.09 million. Equities analysts expect that Agenus will post -12.55 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Agenus

Hedge funds have recently made changes to their positions in the stock. EP Wealth Advisors LLC purchased a new position in shares of Agenus during the 3rd quarter worth approximately $55,000. Corton Capital Inc. purchased a new position in shares of Agenus during the 4th quarter worth approximately $36,000. Point72 DIFC Ltd boosted its position in shares of Agenus by 380.0% during the 3rd quarter. Point72 DIFC Ltd now owns 14,579 shares of the biotechnology company’s stock worth $80,000 after purchasing an additional 11,542 shares during the period. Virtu Financial LLC purchased a new position in shares of Agenus during the 4th quarter worth approximately $51,000. Finally, Apollon Wealth Management LLC purchased a new position in shares of Agenus during the 4th quarter worth approximately $55,000. Hedge funds and other institutional investors own 61.46% of the company’s stock.

Agenus Company Profile

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.